The role of metformin in the management of polycystic ovary syndrome

The document from December 2003 reviews the use of metformin in the management of polycystic ovary syndrome (PCOS), highlighting its role in improving insulin resistance, reducing androgen production, and enhancing reproductive outcomes. It references several studies, including those by Unluhizarci et al. (1999), Baysal et al. (2001), Vrbikova et al. (2002), and Ibanez et al. (2001), which demonstrate metformin's positive effects on biochemical changes, body weight, ovulation prediction, and induction. Systematic reviews and clinical trials, such as those by Costello and Eden (2003), Batukan and Baysal (2001), and Heard et al. (2002), support the improved ovulation and pregnancy rates associated with metformin use. The document also discusses the co-administration of metformin with other treatments and its potential to reduce early pregnancy loss. Despite promising results, the document calls for more research, including larger randomized-controlled trials, to confirm these findings and establish long-term safety and efficacy in PCOS management.